MoonLake Immunotherapeutics Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm's Investigation

Core Insights - MoonLake Immunotherapeutics is under investigation by Block & Leviton for potential securities law violations following a significant drop in share price after disappointing Phase 3 trial results [2][4]. Company Performance - Shares of MoonLake Immunotherapeutics fell over 85% in pre-market trading on September 29 due to the failure of one Phase 3 trial to meet its primary endpoint and modest gains in another trial compared to placebo [2]. - The Phase 3 data is considered to fall short of the previously touted Phase 2 MIRA trial results and is lagging behind competing drugs, raising concerns about the drug's commercial viability [2]. Legal Actions - Block & Leviton is investigating the public statements made by MoonLake regarding its drug trials and may file an action to recover losses for investors [4]. - Investors who have lost money on their MoonLake investments are encouraged to contact Block & Leviton for potential recovery options [5]. Investor Eligibility - Any individual who purchased common stock of MoonLake Immunotherapeutics and experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they have sold their shares [3]. Whistleblower Information - Individuals with non-public information about MoonLake are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].